Please assess the completion status of the following clinical trial:

Trial Title: Umbilical Cord Blood Transplant for Congenital Pediatric Disorders

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
INCLUSION CRITERIA:~* Patients less than 18 years of age.~* Patients with a congenital or acquired immunologic, hematological, or metabolic pediatric disease (including SCID) in which stem cell transplantation has been beneficial.~* Related or Unrelated Umbilical Cord Blood Unit with 0-1 antigen mismatch, 5-6 HLA- A and B (at low to intermediate resolution) and DRB1 (at high resolution).~* Total cryopreserved HSC graft cell dose must be 5 x 10\^7 or greater nucleated cells per kilogram recipient body weight.~* Lansky/Karnofsky scores 60 or greater.~* Patient has DLCO \> 50% predicted or FEV1 \> 50%, if applicable.~* Written informed consent and/or signed assent line from patient, parent or guardian.~EXCLUSION CRITERIA:~* Patients with uncontrolled infections as assessed by the principal investigator only. For bacterial infections, patients must be receiving definitive therapy and have no signs of progressing infection for 72 hours prior to starting conditioning. For fungal infections patients must be receiving definitive systemic antifungal therapy and have no signs of progressing infection for 1 week prior to enrollment. Progressing infection is defined as hemodynamic instability attributable to sepsis or new symptoms, worsening physical signs or radiographic findings attributable to infection. Persisting fever without other signs or symptoms will not be interpreted as progressing infection.~* Severe renal disease (creatinine \> 3X normal for age).~* Severe hepatic disease (direct bilirubin \> 3 mg/dL or SGOT \> 500).~* Patients with symptomatic cardiac failure unrelieved by medical therapy or evidence of significant cardiac dysfunction by echocardiogram (shortening fraction \< 20%).~* HIV positive.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Umbilical Cord Blood Transplant Treatment Plan (Type: EXPERIMENTAL): Busulfan, Cytoxan, Fludarabine, Cord Blood Stem Cell Infusion

Based on this trial design, predict the completion outcome and termination type (if applicable).